JP7342124B2 - カプセル製剤 - Google Patents

カプセル製剤 Download PDF

Info

Publication number
JP7342124B2
JP7342124B2 JP2021531035A JP2021531035A JP7342124B2 JP 7342124 B2 JP7342124 B2 JP 7342124B2 JP 2021531035 A JP2021531035 A JP 2021531035A JP 2021531035 A JP2021531035 A JP 2021531035A JP 7342124 B2 JP7342124 B2 JP 7342124B2
Authority
JP
Japan
Prior art keywords
solid solution
peg
capsule formulation
nonionic surfactant
solution capsule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021531035A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022510304A (ja
JP2022510304A5 (https=
Inventor
レディー レレティ マンモハン
ピー． パワーズ ジェイ
Original Assignee
ケモセントリックス，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=70849818&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7342124(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ケモセントリックス，インコーポレイティド filed Critical ケモセントリックス，インコーポレイティド
Publication of JP2022510304A publication Critical patent/JP2022510304A/ja
Publication of JP2022510304A5 publication Critical patent/JP2022510304A5/ja
Application granted granted Critical
Publication of JP7342124B2 publication Critical patent/JP7342124B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2021531035A 2018-11-30 2019-11-27 カプセル製剤 Active JP7342124B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862773848P 2018-11-30 2018-11-30
US62/773,848 2018-11-30
PCT/US2019/063547 WO2020112961A1 (en) 2018-11-30 2019-11-27 Capsule formulations

Publications (3)

Publication Number Publication Date
JP2022510304A JP2022510304A (ja) 2022-01-26
JP2022510304A5 JP2022510304A5 (https=) 2023-03-15
JP7342124B2 true JP7342124B2 (ja) 2023-09-11

Family

ID=70849818

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021531035A Active JP7342124B2 (ja) 2018-11-30 2019-11-27 カプセル製剤

Country Status (31)

Country Link
US (4) US20200170957A1 (https=)
EP (3) EP4487915A3 (https=)
JP (1) JP7342124B2 (https=)
KR (1) KR102586747B1 (https=)
CN (1) CN113164403A (https=)
AR (1) AR117219A1 (https=)
AU (1) AU2019389031B2 (https=)
BR (1) BR112021010285A2 (https=)
CA (1) CA3120999C (https=)
CL (1) CL2021001389A1 (https=)
CY (1) CY1126079T1 (https=)
DK (2) DK3886820T3 (https=)
ES (2) ES2998858T3 (https=)
FI (2) FI3886820T3 (https=)
HR (2) HRP20230551T1 (https=)
HU (2) HUE069633T2 (https=)
IL (1) IL283450B2 (https=)
LT (2) LT4233850T (https=)
MA (2) MA54318B1 (https=)
MD (2) MD3886820T2 (https=)
MX (1) MX2021006242A (https=)
NZ (1) NZ776554A (https=)
PL (2) PL4233850T3 (https=)
PT (2) PT4233850T (https=)
RS (2) RS64250B1 (https=)
SG (1) SG11202105572UA (https=)
SI (2) SI4233850T1 (https=)
SM (2) SMT202400521T1 (https=)
TW (1) TWI827745B (https=)
WO (1) WO2020112961A1 (https=)
ZA (1) ZA202103820B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020112961A1 (en) 2018-11-30 2020-06-04 Chemocentryx, Inc. Capsule formulations
US11603356B2 (en) 2019-11-08 2023-03-14 Chemocentryx, Inc. Amorphous form of a complement component C5a receptor
CN116529241A (zh) * 2020-10-28 2023-08-01 坎莫森特里克斯公司 治疗化脓性汗腺炎的方法
JP7839157B2 (ja) * 2020-10-28 2026-04-01 ケモセントリックス， インコーポレイテッド 化膿性汗腺炎を処置する方法
WO2022140258A1 (en) * 2020-12-21 2022-06-30 Chemocentryx, Inc. Treatment of c3 glomerulopathy using a c5a inhibitor
CN119031903A (zh) * 2022-05-19 2024-11-26 陶氏环球技术有限责任公司 基于peg的聚合物间复合物用于改善bcs ii类药物的增溶的用途
WO2025203055A1 (en) * 2024-03-26 2025-10-02 Council Of Scientific And Industrial Research Encapsulated dihydrofolate formulation for dietary supplementation as effective nutraceutical supplement and method of preparation thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008521807A (ja) 2004-11-24 2008-06-26 メルク エンド カムパニー インコーポレーテッド 置換アミドの経口投与用液体及び半固体医薬製剤
JP2013529647A (ja) 2010-06-24 2013-07-22 ケモセントリックス，インコーポレイティド Ｃ５ａＲアンタゴニスト

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR038681A1 (es) * 2002-02-14 2005-01-26 Solvay Pharm Bv Formulacion oral de solucion solida de una sustancia activa pobremente soluble en agua
DE102005053066A1 (de) 2005-11-04 2007-05-10 Basf Ag Verwendung von Copolymeren als Solubilisatoren für in Wasser schwerlöslichen Verbindungen
CA2689137C (en) * 2007-05-29 2017-05-02 Intrexon Corporation Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
RS54998B1 (sr) 2008-12-22 2016-11-30 Chemocentryx Inc Antagonisti c5ar
NZ602288A (en) * 2010-03-10 2014-02-28 Abbvie Bahamas Ltd Solid compositions comprising amorphous (2r,6s,13as,14ar,16as,z)-n-(cyclopropylsulfonyl)-6-(5-methylpyrazine-2-carboxamido)-5,16-dioxo-2-(phenanthridin-6-yloxy)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a-carboxamide
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9074470B2 (en) 2010-12-27 2015-07-07 Seven Generations Energy Ltd. Methods for drilling and stimulating subterranean formations for recovering hydrocarbon and natural gas resources
WO2015118015A1 (en) 2014-02-05 2015-08-13 Lek Pharmaceuticals D.D. Solid pharmaceutical compositions of androgen receptor antagonists
DK3200791T3 (da) 2014-09-29 2020-05-25 Chemocentryx Inc Fremgangsmåder og mellemprodukter i fremstilling af C5AR- antagonister
JP7339733B2 (ja) 2016-01-14 2023-09-06 ケモセントリックス，インコーポレイティド Ｃ３腎症を処置する方法
EP3439658B1 (en) 2016-04-04 2021-11-24 ChemoCentryx, Inc. Soluble c5ar antagonists
TWI826364B (zh) 2017-04-03 2023-12-21 德商因夫萊亞斯有限公司 活性抑制劑於發炎性疾病之治療
CA3077395A1 (en) 2017-10-30 2019-05-09 Chemocentryx, Inc. Deuterated compounds as immunomodulators
CA3078732A1 (en) 2017-10-31 2019-05-09 Chemocentryx, Inc. C5ar inhibitor reduction of urinary scd163
US11191756B2 (en) 2018-06-07 2021-12-07 Chemocentryx, Inc. Dosing and effect of C5a antagonist with ANCA-associated vasculitis
WO2020112961A1 (en) 2018-11-30 2020-06-04 Chemocentryx, Inc. Capsule formulations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008521807A (ja) 2004-11-24 2008-06-26 メルク エンド カムパニー インコーポレーテッド 置換アミドの経口投与用液体及び半固体医薬製剤
JP2013529647A (ja) 2010-06-24 2013-07-22 ケモセントリックス，インコーポレイティド Ｃ５ａＲアンタゴニスト

Also Published As

Publication number Publication date
EP4487915A3 (en) 2025-03-19
SG11202105572UA (en) 2021-06-29
US20220233453A1 (en) 2022-07-28
IL283450A (en) 2021-07-29
HRP20241735T1 (hr) 2025-02-28
IL283450B2 (en) 2024-06-01
WO2020112961A1 (en) 2020-06-04
US20200170957A1 (en) 2020-06-04
BR112021010285A2 (pt) 2021-08-17
JP2022510304A (ja) 2022-01-26
CN113164403A (zh) 2021-07-23
US20240299306A1 (en) 2024-09-12
AU2019389031B2 (en) 2023-06-15
DK3886820T3 (da) 2023-05-15
CA3120999C (en) 2025-04-01
EP3886820B1 (en) 2023-04-12
LT3886820T (lt) 2023-06-12
PT3886820T (pt) 2023-05-24
MA62992B1 (fr) 2025-01-31
KR20210098489A (ko) 2021-08-10
MX2021006242A (es) 2021-09-10
EP3886820A4 (en) 2022-08-24
CY1126079T1 (el) 2023-11-15
MD4233850T2 (ro) 2025-02-28
PL4233850T3 (pl) 2025-03-17
KR102586747B1 (ko) 2023-10-06
MA54318B1 (fr) 2023-08-31
LT4233850T (lt) 2025-01-27
PL3886820T3 (pl) 2023-08-14
EP3886820B8 (en) 2023-05-17
HUE069633T2 (hu) 2025-04-28
EP4233850A3 (en) 2023-09-20
HUE062551T2 (hu) 2023-11-28
FI4233850T3 (fi) 2024-12-30
EP3886820A1 (en) 2021-10-06
ES2943492T3 (es) 2023-06-13
FI3886820T3 (fi) 2023-05-25
MA54318A (fr) 2021-10-06
RS66362B1 (sr) 2025-01-31
MD3886820T2 (ro) 2023-07-31
ES2998858T3 (en) 2025-02-21
US20250375385A1 (en) 2025-12-11
TW202038952A (zh) 2020-11-01
CA3120999A1 (en) 2020-06-04
AR117219A1 (es) 2021-07-21
HRP20230551T1 (hr) 2023-08-18
EP4487915A2 (en) 2025-01-08
SMT202400521T1 (it) 2025-01-14
US11951214B2 (en) 2024-04-09
ZA202103820B (en) 2026-03-25
AU2019389031A1 (en) 2021-06-17
IL283450B1 (en) 2024-02-01
NZ776554A (en) 2024-12-20
DK4233850T3 (da) 2025-01-02
EP4233850B1 (en) 2024-10-02
SI3886820T1 (sl) 2023-07-31
SMT202300153T1 (it) 2023-09-06
SI4233850T1 (sl) 2025-03-31
TWI827745B (zh) 2024-01-01
RS64250B1 (sr) 2023-06-30
EP4233850A2 (en) 2023-08-30
CL2021001389A1 (es) 2021-12-24
PT4233850T (pt) 2024-12-30

Similar Documents

Publication Publication Date Title
JP7342124B2 (ja) カプセル製剤
JP5778037B2 (ja) ベンダムスチンの経口投与剤
TWI500431B (zh) 苯達莫司汀（ｂｅｎｄａｍｕｓｔｉｎｅ）的口服劑量型
RU2824998C2 (ru) Лекарственные формы в виде капсул
RU2824998C9 (ru) Лекарственные формы в виде капсул
HK40121602A (en) Capsule formulations
HK40098440A (en) Capsule formulations
HK40098440B (en) Capsule formulations
HK40060732B (en) Capsule formulations
HK40060732A (en) Capsule formulations
HK1179865A (en) Oral dosage forms of bendamustine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221124

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230307

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20230307

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230328

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230628

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230801

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230830

R150 Certificate of patent or registration of utility model

Ref document number: 7342124

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150